Gnomestar Craft Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Gnomestar Craft has been growing earnings at an average annual rate of 34%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been declining at an average rate of 49.9% per year.
Wichtige Informationen
34.0%
Wachstumsrate der Gewinne
37.9%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 23.1% |
| Wachstumsrate der Einnahmen | -49.9% |
| Eigenkapitalrendite | n/a |
| Netto-Marge | -566.3% |
| Letzte Ertragsaktualisierung | 31 Dec 2021 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Gnomestar Craft Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -3 | 1 | 0 |
| 30 Sep 19 | 0 | -4 | 2 | 0 |
| 30 Jun 19 | 0 | -4 | 2 | 0 |
| 31 Mar 19 | 0 | -4 | 2 | 0 |
| 31 Dec 18 | 0 | -3 | 2 | 0 |
| 30 Sep 18 | 0 | -3 | 2 | 0 |
| 30 Jun 18 | 0 | -3 | 2 | 0 |
| 31 Mar 18 | 0 | -4 | 3 | 0 |
| 31 Dec 17 | 0 | -4 | 3 | 0 |
| 30 Sep 17 | 0 | -8 | 4 | 0 |
| 30 Jun 17 | 0 | -7 | 4 | 0 |
| 31 Mar 17 | 0 | -6 | 3 | 0 |
| 31 Dec 16 | 0 | -6 | 3 | 0 |
| 30 Sep 16 | 0 | -2 | 1 | 0 |
| 30 Jun 16 | 0 | -3 | 2 | 0 |
| 31 Mar 16 | 0 | -2 | 2 | 0 |
Qualität der Erträge: GNOM is currently unprofitable.
Wachsende Gewinnspanne: GNOM is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: Insufficient data to determine if GNOM's year-on-year earnings growth rate was positive over the past 5 years.
Beschleunigtes Wachstum: Unable to compare GNOM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: GNOM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: GNOM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.